NAB Show announces 2025 Product of the Year and Project of the Year Award winners NAB Show today unveiled the winners of its distinguished 2025 Product of the Year and newly established Project of the Year Awards during a special ceremony at the Las Vegas Convention Center. These h ... ...
“DJI remains committed to empowering filmmakers and creators, and we are thrilled to return to NAB this year. With the newest additions to our Osmo and Ronin product lines, we continue to revolutionize their work through innovative technology solutions,” said Christina Zhang, Senior Director o...
The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-pacl...
Table 2Published results of nab-paclitaxel combination chemotherapy. Ref. Regimen Median OS (months) Median PFS (months) ORR (%) DCR (%) n Shroffet al[8], 2019Nab-paclitaxel + gemcitabine + cisplatin19.211.8458460 Zhanget al[9], 2023Nab-paclitaxel + S-113.2627.570.654 ...
The cash to sales ratio of National Australia Bank is 5.48 What is the reporting currency for National Australia Bank? National Australia Bank reports financial results in AUD What is the latest annual turnover for National Australia Bank?
Results Chemotherapy combined with dual ICI does not confer a significant increase in survival among an unselected population of patients with mPDAC Patients with mPDAC (n = 180) were randomized to two treatment arms: gemcitabine, nab-paclitaxel, durvalumab and tremelimumab (hereafter referred to...
While I was at Asus’ booth, I saw a presentation by Puget Systems’ Matt Bach, who has been doing some great work in benchmarking and hardware analysis, the results of which are freely available on the Puget Systems website. It’s a valuable resource for those trying to find the best...
Based on the Simon's Two-Stage design, if > 13 of 32 patients achieved pCR, the enrollment would proceed to full accrual of 62 patients as planned. If > 29 of 62 patients achieved pCR, we would deem the study to have met the primary endpoint. Results: From Mar 2021 to Jan 2022, ...
All analyses were based on data frozen on December 11, 2023. Results Intravenous P-AscH- increased serum ascorbate levels from micromolar to millimolar levels. P-AscH- added to the gemcitabine + nab-paclitaxel (ASC) increased overall survival to 16 months compared to 8.3 months with gemcitabine ...
Results Patients Between July 2022 and November 2023, 66 patients with mPC from four hospitals in China were enrolled in the PAAG study (Fig. 1a, b). Each patient was analysed for safety and efficacy. The patients that were included had a median age of 60.0 years, were predominantly male ...